{"entity":{"id":"paper-heinrich-kit-mutation-imatinib-response-jco-2003","kind":"paper","name":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour","aka":[],"tldr":"This analysis showed that the type of KIT mutation predicts response to imatinib: tumours with exon 11 mutations responded in over 80 percent of cases, exon 9 mutations in under half, and tumours without a KIT or PDGFRA mutation rarely responded.","summary":"Mutation analysis of tumours from 127 patients with advanced GIST treated with imatinib in the phase 2 B2222 trial, correlating KIT and PDGFRA genotype with response and progression-free survival.\n\nPartial response was 83.5 percent in KIT exon 11-mutant tumours, 47.8 percent in exon 9-mutant tumours and 0 percent in tumours without a detectable KIT or PDGFRA mutation, with corresponding differences in event-free survival.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2003","url":"https://doi.org/10.1200/JCO.2003.04.190"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/14645423/"}],"tags":[],"related":[],"cancers":["gist-kit-exon-11"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2003,"doi":"10.1200/JCO.2003.04.190","pmid":"14645423","authors":"Heinrich MC, Corless CL, Demetri GD, et al.","paperType":"translational","findings":["Response 83.5 percent (exon 11) vs 47.8 percent (exon 9) vs 0 percent (no mutation).","PDGFRA mutations found in a subset of KIT wild-type tumours."],"whatItMeans":"Mutation testing is standard before imatinib in GIST: exon 11 tumours receive 400 mg, exon 9 tumours are dosed at 800 mg, and PDGFRA D842V tumours are given avapritinib instead.","caveats":["Retrospective analysis of a trial cohort."],"changedPractice":true,"participants":127},"route":"/key-papers/paper-heinrich-kit-mutation-imatinib-response-jco-2003/","neighbours":{"cancer":[{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}